When Eli Lilly sued Empower Pharmacy in April 2025, it wasn't just another pharmaceutical trademark dispute. It was the opening salvo in what has become the most consequential legal battle in the history of compounded medications — a case that could determine whether millions of Americans continue to access affordable GLP-1 treatments or lose that option entirely.
Here's the full timeline, what each side is arguing, and what the April 2026 court ruling means for patients.
Why This Case Matters More Than Any Other
Empower Pharmacy isn't a small-time operator. Based in Houston, it's one of the largest compounding pharmacies in the United States, operating both as a 503A state-licensed compounding pharmacy and an FDA-registered 503B outsourcing facility. When Eli Lilly chose to target Empower, they picked the biggest player on the board.
The outcome here will likely set precedent for every compounding pharmacy in America. If Lilly wins, it signals that brand-name manufacturers can use federal courts to shut down compounding competitors even when those pharmacies argue they're serving legitimate patient needs.
The Complete Timeline
April 1, 2025 — The First Filing
Eli Lilly filed suit in the U.S. District Court for the District of New Jersey (Case No. 2:25-cv-02183). The complaint accused Empower of producing and selling unauthorized versions of Mounjaro and Zepbound — Lilly's tirzepatide-based medications — after the FDA had already resolved the tirzepatide shortage in December 2024.
Lilly's core claim: Empower was running "a nationwide scheme to sell its untested products by misleading consumers about their safety and efficacy." The company specifically targeted Empower's Tirzepatide ODT (orally disintegrating tablet), calling it a mass experiment on unsuspecting consumers.
April 2, 2025 — FDA Warning Letter
One day after Lilly's lawsuit, the FDA issued a warning letter to Empower's Texas facility. The letter cited failures to meet 503B outsourcing facility conditions, including deficiencies in sterile drug production practices. The FDA made clear that 503B registration does not equal FDA approval of compounded drugs.
July 25, 2025 — Strategic Refile in Texas
Lilly voluntarily dismissed the New Jersey case and immediately refiled in the U.S. District Court for the Southern District of Texas (Case No. 4:25-cv-03464) — Empower's home turf, and a jurisdiction where GLP-1 compounding cases have been actively litigated. The new complaint alleged violations of the Lanham Act and state consumer protection laws.
October 2025 — Empower Fights Back
Empower filed a motion to dismiss, arguing that Lilly's claims fell outside private enforcement authority and constituted anticompetitive conduct. Empower's position was blunt: this lawsuit was about market control, not patient safety. The company noted that brand-name Mounjaro costs roughly $1,000/month without insurance, while compounded tirzepatide sold during the shortage period ranged from $250 to $400 monthly — a 60–75% reduction.
January 2026 — Strive's Antitrust Countersuit
In a parallel development, Arizona-based Strive Compounding Pharmacy filed an antitrust lawsuit against both Eli Lilly and Novo Nordisk on January 14, 2026. Strive alleged the pharma giants had entered exclusive agreements with telehealth companies that prohibited those platforms from working with compounding pharmacies — effectively cutting off patient access to affordable alternatives.
April 29, 2026 — The Partial Ruling
A federal judge dismissed part of Eli Lilly's lawsuit but allowed key claims to proceed. This mixed ruling means the case is far from over. Lilly's core allegations about misleading marketing and unauthorized compounding survived the motion to dismiss, setting the stage for discovery and potentially a trial.
What Each Side Is Actually Arguing
Eli Lilly's Position
Lilly frames this as a patient safety issue. Their arguments center on three claims: Empower's compounded tirzepatide products haven't undergone FDA safety and efficacy review. Empower uses Lilly's own clinical trial data (from the SURMOUNT and SURPASS programs) to market products that were never tested in those trials. And Empower's Tirzepatide ODT formulation is an untested delivery method that could produce unpredictable absorption and dosing.
Lilly has also been aggressive beyond the courtroom: the company has filed more than 130 lawsuits total against compounders and wellness centers, petitioned the FDA to add tirzepatide to the "Demonstrably Difficult to Compound" list, and joined the OFA v. FDA case as a defendant-intervenor.
Empower's Position
Empower argues this is fundamentally about access and affordability. The company points out that over 100 million Americans cannot access or afford brand-name tirzepatide, and that compounding pharmacies are filling a legitimate gap. Empower maintains it operates lawfully as both a 503A and 503B facility, and that Lilly's strategy — dismiss and refile, coordinate with the FDA, litigate simultaneously on multiple fronts — is designed to "choke out" lawful competition.
The Broader Legal Landscape
This case doesn't exist in a vacuum. As of mid-2026, the GLP-1 compounding legal landscape includes Novo Nordisk's 130+ lawsuits across 32 states (with 44 permanent injunctions obtained), the Strive antitrust countersuit alleging coordinated anti-competitive behavior, the 5th Circuit appeal in OFA v. FDA (oral arguments heard March 30, 2026 — decision still pending), and the FDA's April 30, 2026 proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List entirely.
If that last item goes through after the June 29, 2026 comment period, it would permanently close the door on large-scale 503B compounding of GLP-1 medications — regardless of how the Lilly vs. Empower case resolves.
What This Means for Patients Right Now
If you're currently using compounded tirzepatide, the Lilly vs. Empower case is worth watching but shouldn't trigger immediate panic. Compounded medications prepared under valid prescriptions through licensed 503A pharmacies with legitimate personalization remain available. The legal battle primarily targets mass-scale compounding that produces products "essentially a copy" of FDA-approved drugs.
However, the regulatory window is narrowing. Here's a practical framework for where things stand:
| Scenario | Status (May 2026) | Risk Level |
|---|---|---|
| 503B facility compounding standard-dose tirzepatide | Legally challenged; 503B Bulks List exclusion pending | High |
| 503A pharmacy with personalized prescription | Legal under state law with clinical justification | Moderate |
| Any pharmacy using "sham personalization" | Under active FDA and manufacturer scrutiny | Very High |
| Brand-name via LillyDirect or insurance | Fully legal, expanding access | None |
Our Take
The Lilly vs. Empower case will likely continue through 2026 and into 2027. The April ruling keeping key claims alive means we'll see discovery, depositions, and potentially internal documents from both sides. For patients, the smartest move is to work with verified, licensed providers now — whether compounded or brand-name — while keeping an eye on both the 5th Circuit ruling and the FDA's Bulks List decision.
SkinnyRx
Three delivery formats — injectable, sublingual drops, and oral tablets — all from one provider. 503A compounding with LegitScript verification. Free physician consultation included.
Paid link · Compounded medications are not FDA-approved products.
Embody
Injectable compounded semaglutide from an FDA-registered 503B outsourcing facility. $149 first month, $299/mo ongoing. Includes prescriber consultation, medication, and shipping.
Paid link · Compounded medications are not FDA-approved products.
GobyMeds
Semaglutide bundle from $99/mo, tirzepatide bundle from $133/mo. LegitScript-certified, 503A + 503B sourcing. Free consultation and free shipping. Use code x7X72r to save $25.
Paid link · Code x7X72r saves $25 · Compounded medications are not FDA-approved products.
Gala GLP-1
No price increases as your dose goes up — $179/mo at every dose tier. Compounded semaglutide with physician consultation, medication, and shipping included.
Lock In $179/mo →Paid link · Compounded medications are not FDA-approved products.